Zedníková Iveta, Chylíková Blanka, Šeda Ondřej, Korabečná Marie, Pazourková Eva, Břešťák Miroslav, Krkavcová Miroslava, Calda Pavel, Hořínek Aleš
Institute of Biology and Medical Genetics of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Department of Obstetrics and Gynecology of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Mol Biol Rep. 2020 Jun;47(6):4531-4540. doi: 10.1007/s11033-020-05545-w. Epub 2020 May 30.
Down syndrome (DS) is one of the most common causes of intellectual disability and new approaches allowing its rapid and effective prenatal detection are being explored. In this study, we investigated the diagnostic potential of plasma microRNAs (miRNAs). This study builds upon our previous study in DS placentas, where seven miRNAs were found to be significantly up-regulated. A total of 70 first-trimester plasma samples from pregnant women were included in the present study (35 samples with DS fetuses; 35 with euploid fetuses). Genome-wide miRNA profiling was performed in the pilot study using Affymetrix GeneChip™ miRNA 4.1 Array Strips (18 samples). Selected miRNAs were then analysed in the validation study using quantitative reverse transcription PCR (RT-qPCR; 52 samples). Based on the current pilot study results (12 miRNAs), our previous research on chorionic villi samples (7 miRNAs) and the literature (4 miRNAs), a group of 23 miRNAs was selected for the validation study. Although the results of the pilot study were promising, the validation study using the more sensitive RT-qPCR technique and a larger group of samples revealed no significant differences in miRNA profiles between the compared groups. Our results suggest that testing of the first-trimester plasma miRNAs is probably not suitable for non-invasive prenatal testing (NIPT). Different results could be theoretically achieved at later gestational ages; however, such a result probably would have limited use in clinical practice.
唐氏综合征(DS)是智力残疾最常见的病因之一,目前正在探索能实现快速有效产前检测的新方法。在本研究中,我们调查了血浆微小RNA(miRNA)的诊断潜力。本研究基于我们之前对唐氏综合征胎盘的研究,在该研究中发现7种miRNA显著上调。本研究共纳入了70例孕早期孕妇的血浆样本(35例怀有唐氏综合征胎儿的样本;35例怀有整倍体胎儿的样本)。在初步研究中使用Affymetrix GeneChip™ miRNA 4.1 Array Strips(18个样本)进行全基因组miRNA分析。然后在验证研究中使用定量逆转录PCR(RT-qPCR;52个样本)对选定的miRNA进行分析。基于当前初步研究结果(12种miRNA)、我们之前对绒毛样本的研究(7种miRNA)以及文献(4种miRNA),选择了一组23种miRNA进行验证研究。尽管初步研究结果很有前景,但使用更灵敏的RT-qPCR技术和更大样本量的验证研究显示,比较组之间的miRNA谱没有显著差异。我们的结果表明,孕早期血浆miRNA检测可能不适用于无创产前检测(NIPT)。理论上在孕晚期可能会得到不同结果;然而,这样的结果在临床实践中的用途可能有限。